These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
Nevada
|
||
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
|
6312 Seven Corners Center, # 303
Falls Church, VA
|
22044
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
| Large accelerated filer | o | Accelerated filer | o |
| Non-accelerated filer | o (Do not check if a smaller reporting company) | Smaller reporting company | x |
|
PART 1 - FINANCIAL INFORMATION
|
||
|
PAGE
|
||
|
Item 1.
|
Financial Statements (Unaudited)
|
F-1
|
|
Item 2.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
1
|
|
Item 3.
|
Quantitative and Qualitative Disclosures About Market Risk
|
4
|
|
Item 4.
|
Controls and Procedures
|
4
|
|
PART II - OTHER INFORMATION
|
||
|
Item 1.
|
Legal Proceedings
|
5
|
|
Item 1A.
|
Risk Factors
|
5
|
|
Item 2.
|
Unregistered Sales of Equity Securities and Use of Proceeds
|
5
|
|
Item 3.
|
Defaults Upon Senior Securities
|
5
|
|
Item 4.
|
(Removed and Reserved)
|
5
|
|
Item 5.
|
Other Information
|
5
|
|
Item 6.
|
Exhibits
|
5
|
|
SIGNATURES
|
6
|
|
| Contents | Page(s) | |
| Balance Sheets as of December 31, 2011 (Unaudited) and March 31, 2011 | F-2 | |
| Statements of Operations for the Nine Months Ended December 31, 2011, for the Period from September 29, 2010 (Inception) through December 31, 2010 and for the Period from September 29, 2010 (Inception) through December 31, 2011 (Unaudited) | F-3 | |
| Statements of Operations for the Three Months Ended December 31, 2011 and 2010 (Unaudited) | F-4 | |
| Statement of Stockholders’ Equity for the Period from September 29, 2010 (Inception) through December 31, 2011 (Unaudited) | F-5 | |
| Statements of Cash Flows for the Nine Months Ended December 31, 2011, for the Period from September 29, 2010 (Inception) through December 31, 2010 and for the Period from September 29, 2010 (Inception) through December 31, 2011 (Unaudited) | F-6 | |
| Notes to the Financial Statements (Unaudited) | F-7 |
|
Health Directory, Inc.
|
||||||||
|
(A Development Stage Company)
|
||||||||
|
Balance Sheets
|
||||||||
|
December 31,
2011
|
March 31,
2011
|
|||||||
|
(Unaudited)
|
||||||||
|
Assets
|
||||||||
|
Current assets
|
||||||||
|
Cash
|
$ | 10,381 | $ | 25,000 | ||||
|
Stock subscriptions receivable
|
- | 13,070 | ||||||
|
Total current assets
|
10,381 | 38,070 | ||||||
|
Total assets
|
$ | 10,381 | $ | 38,070 | ||||
|
Liabilities and stockholders' equity
|
||||||||
|
Current liabilities:
|
||||||||
|
Accrued expenses
|
$ | 3,488 | $ | 7,175 | ||||
|
Total current liabilities
|
3,488 | 7,175 | ||||||
|
Total Liabilities
|
3,488 | 7,175 | ||||||
|
Stockholders' equity
|
||||||||
|
Preferred stock: $0.001 par value: 10,000,000 shares authorized;
|
||||||||
|
none issued or outstanding
|
- | - | ||||||
|
Common stock: $0.001 par value: 500,000,000 shares authorized;
|
||||||||
|
3,759,400 and 2,759,400 shares issued and outstanding, respectively
|
3,759 | 2,759 | ||||||
|
Additional paid-in capital
|
86,311 | 37,311 | ||||||
|
Deficit accumulated during the development stage
|
(83,177 | ) | (9,175 | ) | ||||
|
Total stockholders' equity
|
6,893 | 30,895 | ||||||
|
Total liabilities and stockholders' equity
|
$ | 10,381 | $ | 38,070 | ||||
|
See accompanying notes to the financial statements.
|
||||||||
|
Health Directory, Inc.
|
||||||||||||
|
(A Development Stage Company)
|
||||||||||||
|
Statements of Operations
|
||||||||||||
|
For the Nine MonthsEnded
December 31, 2011
|
For the Period from September
29,
2010 (inception) through
December 31, 2010
|
For the Period from
September 29,
2
010
(inception) through
December 31, 2011
|
||||||||||
|
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
||||||||||
|
Revenues
|
$ | - | $ | - | $ | - | ||||||
|
Operating expenses
|
||||||||||||
|
General and administrative expenses
|
1,419 | - | 1,419 | |||||||||
|
Professional fees
|
18,583 | - | 25,758 | |||||||||
|
Compensation - officer
|
54,000 | 2,000 | 56,000 | |||||||||
|
Total operating expenses
|
74,002 | 2,000 | 83,177 | |||||||||
|
Loss before taxes
|
(74,002 | ) | (2,000 | ) | (83,177 | ) | ||||||
|
Income tax provision
|
- | - | - | |||||||||
|
Net loss
|
$ | (74,002 | ) | $ | (2,000 | ) | $ | (83,177 | ) | |||
|
Net loss per common share:
|
||||||||||||
|
- Basic and diluted
|
$ | (0.03 | ) | $ | (0.00 | ) | ||||||
|
Weighted average common shares outstanding
|
||||||||||||
|
- basic and diluted
|
2,868,500 | 2,066,760 | ||||||||||
|
See accompanying notes to the financial statements.
|
||||||||||||
|
Health Directory, Inc.
|
||||||||
|
(A Development Stage Company)
|
||||||||
|
Statements of Operations
|
||||||||
|
For the Three Months
|
||||||||
|
Ended
|
Ended
|
|||||||
|
December 31, 2011
|
December 31, 2010
|
|||||||
|
(Unaudited)
|
(Unaudited)
|
|||||||
|
Revenues
|
$ | - | $ | - | ||||
|
Operating expenses
|
||||||||
|
General and administrative expenses
|
750 | - | ||||||
|
Professional fees
|
4,803 | - | ||||||
|
Compensation
|
51,500 | - | ||||||
|
Total operating expenses
|
57,053 | - | ||||||
|
Loss before taxes
|
(57,053 | ) | - | |||||
|
Income tax provision
|
- | - | ||||||
|
Net loss
|
$ | (57,053 | ) | $ | - | |||
|
Net loss per common share:
|
||||||||
|
- Basic and diluted
|
$ | (0.02 | ) | $ | - | |||
|
Weighted average common shares outstanding
|
||||||||
|
- basic and diluted
|
3,085,500 | 2,067,485 | ||||||
|
See accompanying notes to the financial statements.
|
||||||||
|
Health Directory, Inc.
|
||||||||||||||||||||
|
(A Development Stage Company)
|
||||||||||||||||||||
|
Statement of Stockholders' Equity
|
||||||||||||||||||||
|
For the Period from September 29, 2010 (Inception) through December 31, 2011
|
||||||||||||||||||||
|
Deficit
|
||||||||||||||||||||
|
Common Stock, $0.001 Par Value
|
Additional
|
Accumulated
|
Total
|
|||||||||||||||||
|
Number of
|
Paid-in
|
during the
|
Stockholders'
|
|||||||||||||||||
|
Shares
|
Amount
|
Capital
|
Development Stage
|
Equity
|
||||||||||||||||
|
Balance, September 29, 2010 (inception)
|
2,000,000 | $ | 2,000 | $ | - | $ | - | $ | 2,000 | |||||||||||
|
Contribution to capital
|
- | 100 | - | 100 | ||||||||||||||||
|
Shares issued at $0.05 per share for cash
|
||||||||||||||||||||
|
from December 1, 2010 through March 31, 2011
|
759,400 | 759 | 37,211 | - | 37,970 | |||||||||||||||
|
Net loss
|
(9,175 | ) | (9,175 | ) | ||||||||||||||||
|
Balance, March 31, 2011
|
2,759,400 | 2,759 | 37,311 | (9,175 | ) | 30,895 | ||||||||||||||
|
Shares issued for compensation valued at $0.05 per share
|
||||||||||||||||||||
|
on December 1, 2011
|
1,000,000 | 1,000 | 49,000 | - | 50,000 | |||||||||||||||
|
Net loss
|
(74,002 | ) | (74,002 | ) | ||||||||||||||||
|
Balance, December 31, 2011
|
3,759,400 | $ | 3,759 | $ | 86,311 | $ | (83,177 | ) | $ | 6,893 | ||||||||||
|
See accompanying notes to the financial statements.
|
||||||||||||||||||||
|
Health Directory, Inc.
|
||||||||||||
|
(A Development Stage Company)
|
||||||||||||
|
Statements of Cash Flows
|
||||||||||||
| For the Period from | For the Period from | |||||||||||
|
For the Nine Months
|
September 29, 2010 | September 29, 2010 | ||||||||||
|
Ended
|
(inception) through
|
(inception) through
|
||||||||||
|
December 31, 2011
|
December 31, 2010
|
December 31, 2011
|
||||||||||
|
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
||||||||||
|
Cash flows from operating activities:
|
||||||||||||
|
Net loss
|
$ | (74,002 | ) | $ | (2,000 | ) | $ | (83,177 | ) | |||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||||||
|
Share issued for compensation
|
50,000 | 2,000 | 52,000 | |||||||||
|
Changes in operating assets and liabilities:
|
||||||||||||
|
Accrued expenses
|
(3,687 | ) | - | 3,488 | ||||||||
|
Net cash used in operating activities
|
(27,689 | ) | - | (27,689 | ) | |||||||
|
Cash flows from financing activities:
|
||||||||||||
|
Captial contribution
|
- | - | 100 | |||||||||
| Collection of stock subscription receivable | 13,070 | 13,070 | ||||||||||
|
Proceeds from sale of common stock
|
- | - | 24,900 | |||||||||
|
Net cash provided by financing activities
|
13,070 | - | 38,070 | |||||||||
|
Net change in cash
|
(14,619 | ) | - | 10,381 | ||||||||
|
Cash, beginning of period
|
25,000 | - | - | |||||||||
|
Cash, end of period
|
$ | 10,381 | $ | - | $ | 10,381 | ||||||
|
Supplemental disclosure of cash flows information:
|
||||||||||||
|
Interest aid
|
$ | - | $ | - | $ | - | ||||||
|
Income tax paid
|
$ | - | $ | - | $ | - | ||||||
|
See accompanying notes to the financial statements.
|
||||||||||||
|
Level 1
|
Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
|
|
|
Level 2
|
Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
|
|
|
Level 3
|
Pricing inputs that are generally observable inputs and not corroborated by market data.
|
|
·
|
Expected term of share options and similar instruments: The expected life of options and similar instruments represents the period of time the option and/or warrant are expected to be outstanding. Pursuant to Paragraph 718-10-50-2 of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and employees’ expected exercise and post-vesting employment termination behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate employee termination behavior. The contractual term of share options or similar instruments is used as expected term of share options or similar instruments for the Company if it is a newly formed corporation.
|
|
·
|
Expected volatility of the entity’s shares and the method used to estimate it. An entity that uses a method that employs different volatilities during the contractual term shall disclose the range of expected volatilities used and the weighted-average expected volatility. A thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.
|
|
·
|
Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected contractual life of the option and similar instruments.
|
|
·
|
Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the option and similar instruments.
|
|
·
|
An entity that holds a group of financial assets and financial liabilities whose market risk (that is, interest rate risk, currency risk, or other price risk) and credit risk are managed on the basis of the entity’s net risk exposure may apply an exception to the fair value requirements in ASC 820 if certain criteria are met. The exception allows such financial instruments to be measured on the basis of the reporting entity’s net, rather than gross, exposure to those risks.
|
|
·
|
In the absence of a Level 1 input, a reporting entity should apply premiums or discounts when market participants would do so when pricing the asset or liability consistent with the unit of account.
|
|
·
|
Additional disclosures about fair value measurements
.
|
|
·
|
An entity that holds a group of financial assets and financial liabilities whose market risk (that is, interest rate risk, currency risk, or other price risk) and credit risk are managed on the basis of the entity’s net risk exposure may apply an exception to the fair value requirements in ASC 820 if certain criteria are met. The exception allows such financial instruments to be measured on the basis of the reporting entity’s net, rather than gross, exposure to those risks.
|
|
·
|
In the absence of a Level 1 input, a reporting entity should apply premiums or discounts when market participants would do so when pricing the asset or liability consistent with the unit of account.
|
|
·
|
Additional disclosures about fair value measurements.
|
|
Exhibit Number
|
Description
|
|
|
31.1
|
Certification of Principal Executive Officer and Principal Financial Officer of the Registrant pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
32.1
|
Certification of Principal Executive Officer and Principal Financial Officer of the Registrant pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
HEALTH DIRECTORY, INC.
|
||
|
Date: February 14, 2012
|
By:
|
/s/ Humaira Haider
|
|
Humaira Haider, President
|
||
|
(Duly authorized officer, Principal Executive Officer and Principal Financial Officer)
|
||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|